Clinical Trial Update: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial of a personalized Selinexor-based therapy for relapsed/refractory multiple myeloma. The results have been posted on 2026-03-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-06